Biogen (MEX:BIIB) Beginning Cash Position

: MXN61,633 Mil (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

Biogen's Beginning Cash Position for the quarter that ended in Mar. 2023 was MXN61,633 Mil.

Biogen's quarterly Beginning Cash Position increased from Sep. 2022 (MXN53,236 Mil) to Dec. 2022 (MXN71,659 Mil) but then declined from Dec. 2022 (MXN71,659 Mil) to Mar. 2023 (MXN61,633 Mil).

Biogen's annual Beginning Cash Position declined from Dec. 2020 (MXN57,959 Mil) to Dec. 2021 (MXN27,308 Mil) but then increased from Dec. 2021 (MXN27,308 Mil) to Dec. 2022 (MXN44,088 Mil).

Biogen Beginning Cash Position Historical Data

The historical data trend for Biogen's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Beginning Cash Position

30,901.56

23,095.96

57,959.32

27,308.24

44,088.25

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Beginning Cash Position																45,026.73	35,192.42	53,236.36	71,659.50	61,632.88

Biogen Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Biogen Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Biogen's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.